The NMDA receptor ‘glycine modulatory site’ in schizophrenia: d-serine, glycine, and beyond

Perala, 2007, Lifetime prevalence of psychotic and bipolar I disorders in a general population, Arch Gen Psychiatry, 64, 19, 10.1001/archpsyc.64.1.19 DeLisi, 2006, Understanding structural brain changes in schizophrenia, Dialogues Clin Neurosci, 8, 71, 10.31887/DCNS.2006.8.1/ldelisi 2014, Schizophrenia Working Group of the Psychiatric Genomics C: Biological insights from 108 schizophrenia-associated genetic loci, Nature, 511, 421, 10.1038/nature13595 Bergeron, 1998, Modulation of N-methyl-d-aspartate receptor function by glycine transport, Proc Natl Acad Sci U S A, 95, 15730, 10.1073/pnas.95.26.15730 Wolosker, 1999, Serine racemase: a glial enzyme synthesizing d-serine to regulate glutamate-N-methyl-d-aspartate neurotransmission, Proc Natl Acad Sci U S A, 96, 13409, 10.1073/pnas.96.23.13409 Schell, 1995, d-Serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release, Proc Natl Acad Sci U S A, 92, 3948, 10.1073/pnas.92.9.3948 Hashimoto, 1993, Endogenous d-serine in rat brain: N-methyl-d-aspartate receptor-related distribution and aging, J Neurochem, 60, 783, 10.1111/j.1471-4159.1993.tb03219.x Papouin, 2012, Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists, Cell, 150, 633, 10.1016/j.cell.2012.06.029 Rosenberg, 2013, Neuronal d-serine and glycine release via the Asc-1 transporter regulates NMDA receptor-dependent synaptic activity, J Neurosci, 33, 3533, 10.1523/JNEUROSCI.3836-12.2013 Basu, 2009, Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior, Mol Psychiatry, 14, 719, 10.1038/mp.2008.130 Ehmsen, 2013, d-Serine in glia and neurons derives from 3-phosphoglycerate dehydrogenase, J Neurosci, 33, 12464, 10.1523/JNEUROSCI.4914-12.2013 Yang, 2010, Brain-specific Phgdh deletion reveals a pivotal role for l-serine biosynthesis in controlling the level of d-serine, an N-methyl-d-aspartate receptor co-agonist, in adult brain, J Biol Chem, 285, 41380, 10.1074/jbc.M110.187443 Mothet, 2005, Glutamate receptor activation triggers a calcium-dependent and SNARE protein-dependent release of the gliotransmitter D-serine, Proc Natl Acad Sci U S A, 102, 5606, 10.1073/pnas.0408483102 Miya, 2008, Serine racemase is predominantly localized in neurons in mouse brain, J Comp Neurol, 510, 641, 10.1002/cne.21822 Benneyworth, 2012, Cell selective conditional null mutations of serine racemase demonstrate a predominate localization in cortical glutamatergic neurons, Cell Mol Neurobiol, 32, 613, 10.1007/s10571-012-9808-4 Balu, 2014, d-Serine and serine racemase are localized to neurons in the adult mouse and human forebrain, Cell Mol Neurobiol, 34, 419, 10.1007/s10571-014-0027-z Fossat, 2012, Glial d-serine gates NMDA receptors at excitatory synapses in prefrontal cortex, Cereb Cortex, 22, 595, 10.1093/cercor/bhr130 Martineau, 2013, Storage and uptake of d-serine into astrocytic synaptic-like vesicles specify gliotransmission, J Neurosci, 33, 3413, 10.1523/JNEUROSCI.3497-12.2013 Betz, 2006, Glycine transporters: essential regulators of synaptic transmission, Biochem Soc Trans, 34, 55, 10.1042/BST0340055 Zafra, 1995, Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS, Eur J Neurosci, 7, 1342, 10.1111/j.1460-9568.1995.tb01125.x Cubelos, 2005, Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain, Cereb Cortex, 15, 448, 10.1093/cercor/bhh147 Kessler, 1989, A glycine site associated with N-methyl-d-aspartic acid receptors: characterization and identification of a new class of antagonists, J Neurochem, 52, 1319, 10.1111/j.1471-4159.1989.tb01881.x Hilmas, 2001, The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications, J Neurosci, 21, 7463, 10.1523/JNEUROSCI.21-19-07463.2001 Lugo-Huitron, 2011, On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress, Neurotoxicol Teratol, 33, 538, 10.1016/j.ntt.2011.07.002 Krystal, 1994, Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses, Arch Gen Psychiatry, 51, 199, 10.1001/archpsyc.1994.03950030035004 Lahti, 2001, Effects of ketamine in normal and schizophrenic volunteers, Neuropsychopharmacology, 25, 455, 10.1016/S0893-133X(01)00243-3 Dalmau, 2007, Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma, Ann Neurol, 61, 25, 10.1002/ana.21050 Dalmau, 2011, Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis, Lancet Neurol, 10, 63, 10.1016/S1474-4422(10)70253-2 Steiner, 2013, Increased prevalence of diverse N-methyl-d-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-d-aspartate glutamate receptor encephalitis, JAMA Psychiatry, 70, 271, 10.1001/2013.jamapsychiatry.86 Allen, 2008, Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database, Nat Genet, 40, 827, 10.1038/ng.171 Fromer, 2014, De novo mutations in schizophrenia implicate synaptic networks, Nature, 506, 178, 10.1038/nature12929 Kirov, 2012, De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia, Mol Psychiatry, 17, 142, 10.1038/mp.2011.154 Purcell, 2014, A polygenic burden of rare disruptive mutations in schizophrenia, Nature, 506, 185, 10.1038/nature12975 Weickert, 2013, Molecular evidence of N-methyl-d-aspartate receptor hypofunction in schizophrenia, Mol Psychiatry, 18, 1185, 10.1038/mp.2012.137 Bendikov, 2007, A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia, Schizophr Res, 90, 41, 10.1016/j.schres.2006.10.010 Goltsov, 2006, Polymorphism in the 5′-promoter region of serine racemase gene in schizophrenia, Mol Psychiatry, 11, 325, 10.1038/sj.mp.4001801 Labrie, 2009, Genetic loss of d-amino acid oxidase activity reverses schizophrenia-like phenotypes in mice, Genes Brain Behav, 9, 11, 10.1111/j.1601-183X.2009.00529.x Morita, 2007, A genetic variant of the serine racemase gene is associated with schizophrenia, Biol Psychiatry, 61, 1200, 10.1016/j.biopsych.2006.07.025 Hashimoto, 2005, Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients, Prog Neuropsychopharmacol Biol Psychiatry, 29, 767, 10.1016/j.pnpbp.2005.04.023 Erhardt, 2001, Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia, Neurosci Lett, 313, 96, 10.1016/S0304-3940(01)02242-X Schwarcz, 2001, Increased cortical kynurenate content in schizophrenia, Biol Psychiatry, 50, 521, 10.1016/S0006-3223(01)01078-2 Balu, 2013, Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction, Proc Natl Acad Sci U S A, 110, E2400, 10.1073/pnas.1304308110 DeVito, 2011, Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology, Genes Brain Behav, 10, 210, 10.1111/j.1601-183X.2010.00656.x Carlson, 2011, Dysbindin-1 mutant mice implicate reduced fast-phasic inhibition as a final common disease mechanism in schizophrenia, Proc Natl Acad Sci U S A, 108, E962, 10.1073/pnas.1109625108 Karlsgodt, 2011, Reduced dysbindin expression mediates N-methyl-d-aspartate receptor hypofunction and impaired working memory performance, Biol Psychiatry, 69, 28, 10.1016/j.biopsych.2010.09.012 Belforte, 2009, Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes, Nat Neurosci, 13, 76, 10.1038/nn.2447 Goff, 1995, Dose-finding trial of d-cycloserine added to neuroleptics for negative symptoms in schizophrenia, Am J Psychiatry, 152, 1213, 10.1176/ajp.152.8.1213 Quartermain, 1994, Acute but not chronic activation of the NMDA-coupled glycine receptor with d-cycloserine facilitates learning and retention, Eur J Pharmacol, 257, 7, 10.1016/0014-2999(94)90687-4 Tsai, 2010, Strategies to enhance N-methyl-d-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis, Curr Pharm Des, 16, 522, 10.2174/138161210790361452 Buchanan, 2007, The Cognitive Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments, Am J Psychiatry, 164, 1593, 10.1176/appi.ajp.2007.06081358 Coyle, 2004, The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia, Psychopharmacology (Berl), 174, 32, 10.1007/s00213-003-1709-2 Li, 2013, Identity of endogenous NMDAR glycine site agonist in amygdala is determined by synaptic activity level, Nat Commun, 4, 1760, 10.1038/ncomms2779 Verrall, 2010, The neurobiology of d-amino acid oxidase and its involvement in schizophrenia, Mol Psychiatry, 15, 122, 10.1038/mp.2009.99 Lane, 2013, Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor, JAMA Psychiatry, 70, 1267, 10.1001/jamapsychiatry.2013.2159 Kozak, 2014, Reduction of brain kynurenic acid improves cognitive function, J Neurosci, 34, 10592, 10.1523/JNEUROSCI.1107-14.2014 Schwarcz, 2012, Kynurenines in the mammalian brain: when physiology meets pathology, Nat Rev Neurosci, 13, 465, 10.1038/nrn3257 Herman, 2012, Metabotropic glutamate receptors for new treatments in schizophrenia, Handb Exp Pharmacol, 29, 7 Albuquerque, 2013, Kynurenic acid as an antagonist of alpha7 nicotinic acetylcholine receptors in the brain: facts and challenges, Biochem Pharmacol, 85, 1027, 10.1016/j.bcp.2012.12.014 Paul, 2013, The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-d-aspartate receptors, J Neurosci, 33, 17290, 10.1523/JNEUROSCI.2619-13.2013 Jones, 2012, Muscarinic nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia, Neuropsychopharmacology, 37, 16, 10.1038/npp.2011.199 Lin, 2013, CASK regulates SAP97 conformation and its interactions with AMPA and NMDA receptors, J Neurosci, 33, 12067, 10.1523/JNEUROSCI.0816-13.2013 Wang, 2006, CLC-3 channels modulate excitatory synaptic transmission in hippocampal neurons, Neuron, 52, 321, 10.1016/j.neuron.2006.08.035 Guzman, 2014, Involvement of ClC-3 chloride/proton exchangers in controlling glutamatergic synaptic strength in cultured hippocampal neurons, Front Cell Neurosci, 8, 143, 10.3389/fncel.2014.00143